Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

NCT ID: NCT03483324

Last Updated: 2022-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-24
• Study Completion Date: 2022-01-31

Brief Summary

A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).

Conditions

Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia in Remission; Myelodysplastic Syndromes; Other Acute Leukemias

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Unmanipulated umbilical cord blood plus AB-110

Group Type: EXPERIMENTAL

Unmanipulated Umbilical Cord Blood (UCB)

Intervention Type: BIOLOGICAL

Human leukocyte antigen (HLA) matched umbilical cord blood

AB-110

Intervention Type: BIOLOGICAL

Expanded cord blood stem cells and engineered human endothelial cells

Interventions

Unmanipulated Umbilical Cord Blood (UCB)

Human leukocyte antigen (HLA) matched umbilical cord blood

Intervention Type: BIOLOGICAL

AB-110

Expanded cord blood stem cells and engineered human endothelial cells

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Patients must have received some immunosuppressive chemotherapy in the preceding 3 months.
• Acute myelogenous leukemia (AML):

1. Complete first remission (CR1) at high risk for relapse

2. Complete second remission (CR2).

3. No documented myelofibrosis at screening marrow biopsy

• Acute lymphoblastic leukemia (ALL):

1. Complete first remission (CR1) at high risk for relapse

2. Complete second remission (CR2).

• Other acute leukemias that are of ambiguous lineage or of other types
• Any acute leukemia with marrow aplasia or without adequate count recovery.
• Myelodysplastic Syndrome (MDS)
• Karnofsky score > 70 %.
• Calculated creatinine clearance > 60 ml/min.
• Bilirubin < 1.5 mg/dL, ALT < 3 x upper limit of normal
• Pulmonary function (FVC, FEV1 and corrected DLCO) > 50% predicted.
• Left ventricular ejection fraction > 50%.
• Albumin > 3.0 g/dL.
• Negative antiviral serology:
• Negative human immunodeficiency virus (HIV) antibody.
• Negative human T-lymphotropic virus (HTLV)-1 and 2 antibodies.
• Negative hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV) DNA
• Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)
• For female subjects of childbearing potential:

1. A negative serum pregnancy test

2. Willing to use contraception throughout the study period.

• Male subjects must be willing to use a recommended method of contraception throughout the study period, and to refrain from sperm donation throughout the study period.
• Two appropriate CB units identified for the subject.
• In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.
• Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
• Evidence of a signed informed written consent

Exclusion Criteria

• Pregnancy or breastfeeding.
• Current active, uncontrolled bacterial, viral, or fungal infection
• Prior allogeneic or autologous HCT at any time.
• Active malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.
• Any identified and available 10/10 HLA-matched related donor or 10/10 HLA-matched unrelated donor.
• Have evidence of recipient donor specific anti-HLA antibodies.
• Active central nervous system (CNS) disease at time of screening.
• Documented allergy to DMSO, mouse or bovine proteins, or iron.
• Subject has other conditions that in the opinion of the investigator would place the subject at increased risk for toxicity by participation in the study.
• Psychiatric condition making the patient unlikely to comply with protocol therapy, required tests and follow-up.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

California Institute for Regenerative Medicine (CIRM)

OTHER

Sponsor Role: collaborator

Angiocrine Bioscience

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Finnegan, MD

Role: STUDY_DIRECTOR

Angiocrine Bioscience

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, United States

University of Colorado Cancer Center University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Countries

United States

Other Identifiers

AB-110-001

Identifier Type: -

Identifier Source: org_study_id